氟芬那酸丁酯软膏联合维A酸乳膏治疗慢性湿疹和神经性皮炎疗效观察

目的观察氟芬那酸丁酯软膏联合维A酸乳膏治疗慢性湿疹和神经性皮炎的疗效。方法将入选的174例慢性湿疹和神经性皮炎患者随机分为两组,治疗组每天早晨和中午各1次局部外搽氟芬那酸丁酯软膏,晚上局部外搽0.1%维A酸乳膏1次;对照组局部搽0.05%卤米松乳膏,早、晚各1次,4周后观察疗效,并随访6个月。结果治疗组有效率78.88%,对照组为80.95%,两组有效率比较,差异无显著性意义(P>0.05);治疗组复发率13.89%,对照组为40.63%,两组复发率比较,差异有显著性意义(P<0.05)。结论氟芬那酸丁酯软膏联合维A酸乳膏治疗慢性湿疹和神经性皮炎疗效显著,复发率低。     

卤米松乳膏联合夫西地酸乳膏治疗亚急性或慢性湿疹疗效观察

目的观察比较卤米松乳膏联合夫西地酸乳膏与单独使用卤米松乳膏治疗亚急性或慢性湿疹的临床疗效。方法治疗组交替使用卤米松乳膏和夫西地酸乳膏,2次/d,每次用药间隔大于2h;对照组单独使用卤米松乳膏,2次/d。连续用药2周。结果治疗组63例,治愈率50.8%,有效率90.5%;对照组60例,治愈率35.0%,有效率66.6%;两组有效率比较差异有统计学意义(P<0.05)。结论交替使用卤米松乳膏和夫西地酸乳膏治疗亚急性或慢性湿疹效果较好,无明显不良反应。     

卤米松乳膏治疗皮炎湿疹140例疗效分析

目的探讨卤米松乳膏治疗皮炎湿疹患者的疗效。方法将来我院皮肤科治疗的140例皮炎湿疹患者作为研究对象,随机将其分为两组,对照组患者70例,利用糠酸莫米松乳膏对其实施治疗;实验组患者70例,利用卤米松乳膏对其实施治疗。比较两组治疗效果与不良反应。结果对照组患者治疗有效率为67.14%,实验组患者治疗有效率为92.86%,两组实验结果具有显著差异,即P0.05。结论卤米松乳膏对皮炎湿疹患者有良好的治疗效果,可广泛应用在皮肤病临床治疗中。     

湿疹及皮炎

20060198 变应性皮肤瘸患血清IgE和ECP分析；20060199 卤米松乳膏治疗湿疹皮炎等皮肤瘸疗效观察；20060200 0．1％糠酸莫米松乳膏治疗皮炎湿疹临床疗效观察；20060201 用瘙瘁直观比例卡等评价卤米松乳膏对皮炎湿疹的疗效；20060202 未分类湿疹患血清白细胞介素12水平研究；……[编按]     

外用川百止痒洗剂联合0.1%糠酸莫米松乳膏治疗湿疹临床研究

目的观察川百止痒洗剂联合0.1%糠酸莫米松乳膏治疗湿疹的有效性与安全性。方法采用随机、单盲、平行对照的方法对63例湿疹患者应用川百止痒洗剂联合0.1%糠酸莫米松乳膏外用治疗,同时设立对照组64例单独外用0.1%糠酸莫米松乳膏,治疗12天后评价疗效,并进行皮肤病生活质量指数(dermatology life quality index,DLQI)问卷调查。结果试验组总有效率为87.30%,与对照组70.31%相比有统计学差异(P<0.01);DLQI总分两组均下降,但无统计学差异(P=0.8775);试验组和对照组发生局部刺激反应分别为6.3%和7.8%,无统计学差异(Fisher校正χ2检验P=1.0000)。结论川百止痒洗剂联合0.1%糠酸莫米松乳膏治疗湿疹较为有效、安全。     

0.1%糠酸莫米松乳膏治疗皮炎湿疹临床疗效观察

目的观察0.1%糠酸莫米松乳膏对皮炎湿疹的疗效。方法110例皮炎湿疹患者用0.1%糠酸莫米松乳膏薄涂患处,1次/d,疗程3周。结果治愈率80.9%,有效率92.7%,未见不良反应。结论0.1%糠酸莫米松乳膏治疗皮炎湿疹疗程短,疗效好,是一种有效、安全、方便的皮肤病外用药。     

卤米松乳膏治疗皮炎、湿疹的疗效观察

我科自2004年2月至今外用卤米松乳膏治疗84例慢性湿疹,亚急性湿疹和神经性皮炎患者,获得较满意疗效.现总结报道如下.     

糠酸莫米松乳膏治疗湿疹皮炎类皮肤病多中心临床研究

目的 评价0.1%糠酸莫米松乳膏治疗湿疹皮炎类皮肤病疗效和安全性。方法 本研究采用随机、双盲、平行对照的临床研究方法。受试者分别接受国产糠酸莫米松乳膏和艾洛松治疗。患者每日局部涂药1次,连续用药4周。在治疗始及治疗后第1～4周对各观察指标进行评估记录。结果 本研究共入选受试者284例(试验组和对照组各142例)中湿疹143例,神经性皮炎141例。治疗后1～4周,两组患者各项症状/体征指标计分及总计分均有明显下降。试验组和对照组组间比较差异无统计学意义。治疗结束时,湿疹患者试验组基愈率和总有效率分别为78.87%、97.18%;对照组基愈率和总有效率分别为84.51%、92.96%。神经性皮炎患者试验组基愈率和有效率分别为75.71%、100%;对照组基愈率和总有效率分别为80.28%、94.37%。两组患者总体评价试验组基愈率77.30%,有效率98.58%。对照组基愈率82.39%,有效率93.64%。两组间疗效比较差异无统计学意义。研究中两组均未发生不良反应。试验组发生接触性皮炎1例。结论 0.1%糠酸莫米松乳膏治疗湿疹、神经性皮炎使用方便,安全性好。     

0.05%卤米松治疗皮炎湿疹的临床疗效观察

0.05%卤米松(商品名:澳能)为新一代超强效外用糖皮质激素制剂.笔者2003年7月-2004年3月采用澳能乳膏治疗103例慢性湿疹、亚急性湿疹和神经性皮炎患者,取得了一定疗效,现报告如下.     

窄谱中波紫外线联合卤米松乳膏治疗掌跖角化性湿疹疗效观察

目的观察窄谱中波紫外线联合卤米松乳膏治疗掌跖角化性湿疹的疗效。方法将70例掌跖角化性湿疹患者分成两组,治疗组35例应用窄谱中波紫外线联合卤米松乳膏治疗;对照组35例应用卤米松乳膏治疗。结果3周后治疗组有效率85.71%,对照组51.43%,差异有统计学意义(χ~2=9.55,P<0.05)。结论窄谱中波紫外线联合卤米松乳膏治疗掌跖角化性湿疹疗效较好。     

Unique immunobullous disease in a child with a predominantly IgA response to three desmosomal proteins

Chronic hand eczema can be incapacitating, and there is little knowledge of the efficacy and safety of long-term treatment with topical corticosteroids. We compared the efficacy and safety of two different schedules for the treatment of chronic hand eczema with a potent topical corticosteroid, mometasone furoate. In a prospective, open, randomized trial, 120 patients with chronic hand eczema were treated daily with mometasone furoate fatty cream until the dermatitis cleared or for a maximum of 9 weeks. Those who cleared were randomized to treatment for up to 36 weeks with mometasone furoate on Sunday, Tuesday and Thursday (group A), mometasone furoate on Saturday and Sunday (group B) or no further corticosteroid treatment (group C). In the event of relapse, patients were permitted daily treatment with mometasone furoate for 3 weeks on two separate occasions. For 50 of 106 randomized patients, daily treatment for 3 weeks controlled their dermatitis; 29 needed 6 weeks and 27 needed 9 weeks of treatment. During the maintenance phase, 29 of 35 (83%) in group A, 25 of 37 (68%) in group B and nine of 34 (26%) in group C had no recurrences (P = 0.001, chi2-test). Side-effects were minimal. It is concluded that long-term, intermittent treatment of chronic hand eczema with mometasone furoate fatty cream is effective and safe.     

复方甘草酸苷联合维A酸乳膏和糠酸莫米松乳膏治疗寻常性银屑病疗效观察

目的探讨复方甘草酸苷联合维A酸乳膏和糠酸莫米松乳膏治疗寻常性银屑病的临床疗效。方法165例患者随机分为两组,试验组81例,口服复方甘草酸苷联合维A酸乳膏和糠酸莫米松乳膏外用;对照组84例,仅外用维A酸乳膏和糠酸莫米松乳膏,疗程均为4周,随访3个月。结果试验组有效率为76．54％,明显高于对照组（48．81％）（P〈0．01）;试验组不良反应发生率为13．58％,比对照组低（20．24％）（P〈0．05）;试验组治愈患者复发率为24．00％,低于对照组（36．00％）（P〈O．05）。结论复方甘草酸苷联合维A酸乳膏和糠酸莫米松乳膏外用治疗寻常性银屑病疗效优于仅给予维A酸乳膏和糠酸莫米松乳膏外用,且患者不良反应和复发率明显降低。     

0.05%地奈德乳膏治疗三种常见皮肤病的疗效观察

目的评价0.05%地奈德乳膏治疗特应性皮炎、脂溢性皮炎及寻常性银屑病的临床疗效及安全性。方法采用开放式研究。分别应用0.05%地奈德、1%丁酸氢化可的松及0.1%糠酸莫米松乳膏治疗特应性皮炎、脂溢性皮炎及寻常性银屑病。对患者治疗前后红斑、糜烂、浸润、丘疹、渗出/结痂、瘙痒及皮损面积的总积分进行评价。结果治疗2周后,地奈德组的临床疗效明显优于丁酸氢化可的松组,差异有显著性(P<0.05),两组均未见明显不良反应;地奈德组的疗效与糠酸莫米松组相当(P>0.05),但后者有1例出现瘙痒,1例出现红斑加重。结论应用0.05%地奈德乳膏治疗特应性皮炎、脂溢性皮炎及寻常性银屑病疗效可靠,临床使用安全。     

SAFETY AND EFFICACY OF MOMETASONE FUROATE CREAM IN THE TREATMENT OF STEROID RESPONSIVE DERMATOSES

The safety and efficacy of once daily application of mometasone furoate cream 0.1% was determined by comparison with twice daily applications of betamethasone dipropionate cream 0.05% in a single blind, dual centre, randomized study in patients with a variety of steroid-responsive inflammatory dermatoses, the most common of which was psoriasis. Morning plasma cortisol levels revealed little adrenal suppression in either of the two study groups and there was no significant difference between the two groups. Routine laboratory investigations showed no trends in values outside the normal ranges that were of clinical significance. Less skin atrophy was seen in the group treated with mometasone furoate. In comparison to the betamethasone dipropionate treated group, those treated with mometasone furoate exhibited only slight evidence of skin atrophy, and this was not observed before four to twelve weeks of treatment. Eighteen percent of patients using mometasone reported adverse reactions but all were of limited duration and did not persist despite continued application of the drug. Nine percent of patients using betamethasone dipropionate reported adverse effects. Both drugs were found to be highly effective with no significant difference between the two groups at the termination of the treatment period. Of importance is the fact that whilst mometasone furoate is found to be a highly effective treatment for a variety of steroid-responsive dermatoses, this drug has only a limited potential for production of local and systemic side effects. Thus, a high margin of safety can be expected for patients using this drug.     

卡介菌多糖核酸联合他扎罗汀等治疗寻常性银屑病疗效观察

目的观察卡介菌多糖核酸联合外用他扎罗汀及糠酸莫米松治疗寻常性银屑病临床疗效。方法患者随机分为两组。治疗组120例采用卡介菌多糖核酸2mL肌注,隔日1次,18次为1疗程;2mL肌注隔2日1次,18次为第2疗程;同时予他扎罗汀凝胶每晚外涂,糠酸莫米松乳膏隔日早晨外涂。对照A组80例仅肌注卡介菌多糖核酸,用法同治疗组;对照B组98例仅外涂他扎罗汀凝胶及糠酸莫米松乳膏,用法同治疗组。结果治疗组有效率91.66%,对照A,B组分别为86.25%,64.78%。治疗组与对照组比较差异有显著性(P1=0.0034,P2<0.0001)。结论卡介菌多糖核酸联合他扎罗汀凝胶及糠酸莫米松乳膏治疗寻常性银屑病疗效确切。     

Topical tacrolimus (FK506) and mometasone furoate in treatment of dyshidrotic palmar eczema: a randomized, observer-blinded trial.

BACKGROUND: Dyshidrotic palmoplantar eczema is a frequent disease often running a chronic relapsing course. Topical glucocorticosteroids form the mainstay of therapy, and alternatives are urgently warranted. OBJECTIVE: This study was performed to compare the efficacy of tacrolimus (FK506) 0.1% ointment and mometasone furoate 0.1% ointment in the treatment of dyshidrotic palmoplantar eczema. METHODS: Sixteen patients were included in the study after a randomized, observer-blind, intrapersonal comparison protocol. After a 2-week washout period, the active treatment phase amounted to 4 weeks with twice-daily topical application of test substances and additional use of emollients at will. Thereafter, patients were monitored at weekly intervals up to 8 weeks. RESULTS: The dyshidrotic area and severity index showed a more than 50% reduction of baseline values after 2 weeks of active treatment both for FK506 (P =.003) and mometasone furoate (P =.022) in palmar areas. After active treatment, a nonsignificant increase in the dyshidrotic area and severity index was seen with FK506 treated areas. Fourteen of 16 patients had recurring symptoms requiring further therapy within 3 weeks after the active treatment phase. CONCLUSION: Treatment with FK506 offers the possibility for rotational therapy with mometasone furoate in long-standing cases of chronic dyshidrotic palmar eczema.     

A pilot study on the efficacy of mometasone furoate fatty cream on clinical parameters, time to relapse and microbial flora in atopic dermatitis

Aim To study the antimicrobial effect in vitro of hexylene glycol and mometasone furoate fatly cream (contains 12% hexylene glycol) and to study the effect of mometasone furoate fatty cream on clinical parameters and microbial flora in patients with atopic dermatitis. Methods The effect of hexylene glycol and mometasone furoate fatty cream against Staphylococcus aureus, S. epidermidis, Pityrosporum ovule and Candida albicans was studied in vitro. Twenty patients with moderate to severe atopic dermatitis were treated with mometasone furoate 0.1 % fatty cream once daily for 3 weeks and then intermittently for 3 weeks. Quantitative cultures for bacteria and fungi were taken at baseline, during treatment and 4 weeks after end of treatment. Results Both hexylene glycol and mometasone furoate fatty cream were effective in vitro against the studied microorganisms. Thirteen of 18 patients who returned for control were cleared after 3 weeks of treatment and 15/18 patients or 83% were cleared after 6 weeks. Four weeks after end of treatment only one patient remained cleared. However, 11/14 patients who returned for this control were still improved compared to baseline. S aureus was cultured in 16/20 patients at baseline but in only 7/18 patients after 6 weeks of treatment. The number of S. aureus dropped significantly but increased two-fold 4 weeks after end of treatment. The number of cultured P. ovale was also significantly reduced after 6 weeks. Conclusion This study clearly demonstrate the good effect of mometasone furoate fatty cream, which contains 12% hexylene glycol, in the treatment of atopic dermatitis paralleled by a significant reduction in the number of S. aureus and P. ovale.     

The Clinical Efficacy of Mometasone Furoate in Multi-Lamellar Emulsion for Eczema: A Double-blinded Crossover Study

Background

Topical application of corticosteroids also has an influence on skin barrier impairment. Physiological lipid mixtures, such as multi-lamellar emulsion (MLE) containing a natural lipid component leads to effective recovery of the barrier function.

Objective

The purpose of this study was to conduct an evaluation of the therapeutic efficacy and skin barrier protection of topical mometasone furoate in MLE.

Methods

A multi-center randomized, double-blind, controlled study was performed to assess the efficacy and safety of mometasone furoate cream in MLE for Korean patients with eczema. The study group included 175 patients with eczema, who applied either mometasone furoate in MLE cream or methylprednisolone aceponate cream for 2 weeks. Treatment efficacy was evaluated using the physician''s global assessment of clinical response (PGA), trans-epidermal water loss (TEWL), and visual analogue scale (VAS) for pruritus. Patients were evaluated using these indices at days 4, 8, and 15.

Results

Comparison of PGA score, TEWL, and VAS score at baseline with those at days 4, 8, and 15 of treatment showed a significant improvement in both groups. Patients who applied mometasone furoate in MLE (74.8%) showed better results (p<0.05) than those who applied methylprednisolone aceponate (47.8%). The TEWL improvement ratio was higher in the mometasone furoate in MLE group than that in the methylprednisolone aceponate group, and VAS improvement was also better in the mometasone furoate in MLE group.

Conclusion

Mometasone furoate in MLE has a better therapeutic efficacy as well as less skin barrier impairment than methylprednisolone aceponate.